Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Lexeo Therapeutics will host an educational investor webcast on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy on October 21, 2026 at 1:00 PM ET. The event features Chief Medical Officer Narinder Bhalla and Cleveland Clinic physician-scientist Alessio Gasperetti discussing disease-burden assessment and treatment-response measures relevant to its LX2020 program.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.